Spiegel Reuven sold $657K of DK

Spiegel Reuven (EVP, Delek Logistics) sold 10,000 shares of Delek US Holdings, Inc. (DK) at $65.72 ($0.66M total) on 2026-11-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Spiegel Reuven
Published Nov 21, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DK
Neutral
high confidence
Mentioned
$DK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DKNeutralLow
01

Why it matters

The disclosed event is an officer open-market sale totaling $657,200, executed under a pre-arranged Rule 10b5-1 plan, which typically lowers the signal strength versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a material repricing without additional company-specific catalysts.

03

What to watch

The article provides only the sale details; it does not include any offsetting insider buys, broader insider activity trends, or changes in company fundamentals.

Relevance 4/10Novelty 4/10Timing: latest Form 4 filed 2026-11-20, covering sale dated 2026-11-18

Background

The article is a SEC Form 4 insider transaction disclosure for Delek US Holdings, Inc. (DK).

Company-level read

Ticker impact

$DKNeutralHigh confidence
Context

Delek US Holdings disclosed an EVP open-market sale of 10,000 shares at $65.72 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact, with traders treating it as routine 10b5-1 selling rather than a directional catalyst.

Evidence & confidence

The filing is a Form 4 insider transaction, but it is explicitly tied to a pre-arranged 10b5-1 plan and lacks any accompanying operational or guidance change.

Market effects

No clear sector read-through from a single routine 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with valuation or liquidity needs, so some traders may still fade short-term sentiment.

Key entities

  • Delek US Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Spiegel Reuven

    EVP at Delek Logistics, reported the sale.

  • Rule 10b5-1 plan

    Pre-arranged plan cited as Yes, reducing interpretive weight.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DKMed

Why is Delek US stock rallying today?

Delek US Holdings (DK) stock rose 5.1% after an analyst upgrade to Buy with a $88 price target, citing strong Q3 2026 earnings. The company reported adjusted EPS of $13.55 and revenue of $4.39B, exceeding estimates. The board increased the dividend by 18% and authorized $100M in share repurchases. Institutional investors, holding 97% of shares, have been active in recent filings.

$DKHighAI 8/10

Freedom Broker upgrades Delek US stock rating on strong earnings

Freedom Broker upgraded Delek US (NYSE:DK) to Buy, raising its price target to $88. The company reported strong Q3 earnings, with adjusted net income nearly doubling to $843.0 million. DK cut net debt by $506.4 million and increased its dividend by 18%. The stock trades at a P/E ratio of 3.31 with a free cash flow yield of 32%. Raymond James also raised its price target to $95, citing strong macroeconomic conditions and operational improvements.

$DKMedAI 8/10

Delek US Holdings Inc (DK) (Q3 2026) Earnings Call Highlights: Record Net Income, Raised

Delek US Holdings Inc (DK) reported Q3 2026 net income with $809M working capital outflow, $4.6M asphalt segment loss, and no DKTS guidance due to market volatility. CEO Soreq highlighted SRE benefits, cash flow plans, and EOP improvements. Analysts noted RIN uncertainty and El Dorado refinery's low capture rate. The company expects $700M-$800M mid-cycle free cash flow and maintains a disciplined capital allocation strategy.

$DKMedAI 8/10

Delek US Holdings (DK) Q3 2026 Earnings Call Transcript

Delek US Holdings (DK) reported Q3 2026 net income of $1.13B ($18.22/ share) and EBITDA of $1.64B. The company raised its EOP target to $250M annually and expects $425M in SRE proceeds. DKL increased 2026 EBITDA guidance to $530M-$560M. Delek plans $100M in share buybacks and raised its dividend to $0.30/share.